ArticleAging2025
Methods for joint modeling of longitudinal omics data and time-to-event outcomes: applications to lysophosphatidylcholines in connection to aging and mortality in the Long Life Family Study.
Article in Aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Embracing non-linearity in human ageing.Nature reviews. Genetics · 2026Review
- Erythrocyte Count, Anemia, and the Human Natural Lifespan Limit: Evidence from the Long Life Family Study.bioRxiv : the preprint server for biology · 2026Article
- A pretreatment 15-gene signature predicts non-pCR in response to neoadjuvant chemotherapy in breast cancer and reveals a pyruvate-Frontiers in oncology · 2026Article
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
Studying the relationships between longitudinal changes in omics variables and event risks requires specific methodologies for joint analyses of longitudinal and time-to-event outcomes. We applied two such approaches (joint models [JM], stochastic process models [SPM]) to longitudinal metabolomics data from the Long Life Family Study, focusing on the understudied associations of longitudinal changes in lysophosphatidylcholines (LPCs) with mortality and aging-related outcomes. We analyzed 23 LPC species, with 5,066 measurements of each in 3,462 participants, 1,245 of whom died during follow-up. JM analyses found that higher levels of the majority of LPC species were associated with lower mortality risks, with the largest magnitude observed for LPC 15:0/0:0 (hazard ratio: 0.71, 95% CI (0.64, 0.79)). SPM applications to LPC 15:0/0:0 revealed that the JM association reflects underlying aging-related processes: a decline in robustness to deviations from optimal LPC levels, higher equilibrium LPC levels in females, and the opposite age-related changes in the equilibrium and optimal LPC levels (declining and increasing, respectively), which lead to increased mortality risks with age. Our results support LPCs as biomarkers of aging and related decline in biological robustness, and call for further exploration of factors underlying age-related changes in LPC in relation to mortality and diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.